Endpoints News
"When it’s rushed this way, this is what happens" Read in browser
Endpoints News
Thank you for reading, dupa dupackia!
basic
UPGRADE
M T Wed Th F
2 September, 2026
Endpoints 11 - Reserve Your Spot - Save $100 with our Early Bird rate
One night, one room: the founders, scientists and investors behind the Endpoints 11, together in Boston this September. Reserve your spot now and save with the early bird rate.
presented by Riyadh Global Medical Biotechnology
How the Riyadh Glob­al Med­ical Biotech­nol­o­gy Sum­mit is de-risk­ing Sau­di Ara­bi­a's cell and gene ther­a­py am­bi­tions
top stories
1.
in focus
China deaths reignite debate about using viruses to deliver CRISPR therapies
2. Teva reports a single-shot success in celiac disease, heating the IL-15 market
3.
news briefing
UK regulator halts sales of Tavneos; UniQure seeks approval for Huntington's gene therapy
4. Exclusive: Typewriter raises $56M for jumping-gene tech, in vivo CAR-T
5. Three takeaways from the latest White House drug pricing event
6. ARPA-H awards $125M for manufacturing custom RNA therapies on demand
7. Arsenal Biosciences cuts ‘majority’ of staff in move to in vivo CAR-T
more stories
• 
Drew Armstrong
.

We're three weeks out from the Endpoints 11, our annual list of the most exciting startups in biotech. Join us on Sept. 24 in Boston for an evening of innovation, conversation and the unveiling of the new companies defining the future of medicine.
.
Drew Armstrong
Executive Editor, Endpoints News
@ArmstrongDrew
.
Endpoints In Focus
1
by Ryan Cross

The deaths of two chil­dren who re­ceived CRISPR ther­a­pies in Chi­na have rat­tled sci­en­tists who work on sim­i­lar ge­net­ic med­i­cines in the US, adding new...

Read the full story
2
by Andrew Dunn

A sin­gle in­jec­tion of an ex­per­i­men­tal an­ti­body sig­nif­i­cant­ly re­duced in­testi­nal dam­age among peo­ple with celi­ac dis­ease who then ate gluten dai­ly, Te­va Phar­ma­ceu­ti­cals said Wednes­day...

Read the full story
News Briefing: Quick hits from the biopharma web
3
by ENDPOINTS

Plus, news about Re­gen­eron, Novo­cure, Jaz­z's Zi­ihera, Bio­Marin, As­cendis, As­traZeneca, Hutchmed and TScan Ther­a­peu­tics.

An­oth­er road bump for Tavneos: The Med­i­cines and Health­care prod­ucts...

Read the full story
GLOBAL PHARMA AND BIOTECH SUMMIT - Rewriting the rules of growth, access and innovation - Register now
Drugs worth $180bn in annual revenue are heading off patent, and the industry holds an estimated $1.3tn to fill the gap. Hear how leaders from Novartis, Novo Nordisk and GSK are positioning for what comes next. Register now.
Typewriter CEO Matthew Stanton (L) and CSO Leanne Peiser
4
by Ryan Cross

Mov­ing pieces of ge­net­ic code com­mon­ly called “jump­ing genes” could give sci­en­tists a long-sought way to trans­plant full genes in­to the hu­man body...

Read the full story
5
by Max Bayer

Pres­i­dent Don­ald Trump an­nounced vol­un­tary drug pric­ing deals with nine new com­pa­nies on Mon­day, for the first time veer­ing out­side of the orig­i­nal crop of...